Tradestie Institutional Equity Comparison Engine

CING vs ANRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANRO Overall Edge

ANRO Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical while CING counters with relative strength in Options & Structure. Fundamentally, CING trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CING N/M vs ANRO N/M Fwd P/E
Growth & Margin Winner ANRO
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner ANRO
1Y +36.4% vs +107.3% ยท 52W Pos 18% vs 54%
Options & Structure Winner CING
BREAKDOWN (16th %ile IV) vs BREAKDOWN (8th %ile IV)
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
1M Return +9.17%
1Y Return +36.39%
Forward P/E N/M
Unified AI Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.11
-7.41% 1D
Market Cap $1.2B
1M Return +10.04%
1Y Return +107.35%
Forward P/E N/M
Unified AI Score
34.3 / 100 SELL
Tech 15.0 Fund 38.0 Flow 64.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CING +36.39% ANRO +107.35% Spread: +70.96 pp (ANRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CING TTM Op. Margin: 0.0% ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs ANRO. Trailing 12-month operating profitability (CING 0.0% vs ANRO 0.0%) and valuation multiples (CING N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CING (1) vs ANRO (4)
Institutional Metric CING ANRO Criterion Row Winner
Market Capitalization Scale $62.5M $1.2B Larger Scale ANRO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -198.7% -46.7% Higher ROE ANRO
52-Week Range Position Momentum 18% ($3โ€“$12) 54% ($11โ€“$37) Stronger Trend ANRO
Beta / 30D Volatility Risk Regime 1.13ฮฒ ยท 117% Vol 2.02ฮฒ ยท 93% Vol Lower Realized Risk ANRO
Unified Institutional Score Composite Signal 44.8 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite CING

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CING vs ANRO Buy Guide
CING BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live CING Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ANRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CING nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.